Stockard has completed the interview portion of the competition and is now preparing for on-stage competition, which, for her, begins Wednesday.

Sophie Pierce is determined to make the most of her life - however long she may have.

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

KIT-2014 is under development for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. The therapeutic candidate acts by targeting phosphoinositide 3-kinase gamma. It is ...

LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...